Edward Dow

434 total citations
15 papers, 276 citations indexed

About

Edward Dow is a scholar working on Hematology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Edward Dow has authored 15 papers receiving a total of 276 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Hematology, 7 papers in Molecular Biology and 4 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Edward Dow's work include Multiple Myeloma Research and Treatments (5 papers), Protein Degradation and Inhibitors (3 papers) and Lung Cancer Treatments and Mutations (3 papers). Edward Dow is often cited by papers focused on Multiple Myeloma Research and Treatments (5 papers), Protein Degradation and Inhibitors (3 papers) and Lung Cancer Treatments and Mutations (3 papers). Edward Dow collaborates with scholars based in United States, Japan and Belgium. Edward Dow's co-authors include Peter L. Turecek, Flora Peyvandi, Jacob J. Lokich, Erik Berntorp, Murray M. Bern, Peter A. Kouides, Liviu Niculescu, Helgi van de Velde, Jesús F. San Miguel and Kenneth C. Anderson and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Edward Dow

15 papers receiving 263 citations

Peers

Countries citing papers authored by Edward Dow

Since Specialization

Citations

This map shows the geographic impact of Edward Dow's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Edward Dow with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Edward Dow more than expected).

Fields of papers citing papers by Edward Dow

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Edward Dow. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Edward Dow. The network helps show where Edward Dow may publish in the future.

Co-authorship network of co-authors of Edward Dow

This figure shows the co-authorship network connecting the top 25 collaborators of Edward Dow. A scholar is included among the top collaborators of Edward Dow based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Edward Dow. Edward Dow is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

#	Work	Indexed citations
1	Early progression and transformation of a splenic diffuse red pulp small B-cell lymphoma with NOTCH1, ARID2, CREBBP, and TNFRSF14 gene mutations 2023 ·Leukemia Research Reports ·(unknown), (unknown), (unknown), (unknown), (unknown), Edward Dow, Olga Kozyreva	2
2	DSP-0390, an oral emopamil binding protein (EBP) inhibitor, in patients with recurrent high-grade glioma: A first-in-human, phase 1 study. 2022 ·Journal of Clinical Oncology ·David A. Reardon, Yoshitaka Narita, Yoshiki Arakawa, Samuel Goldlust, George Ansstas, Jian Mei, Edward Dow, (unknown), (unknown), (unknown), (unknown)	2
3	Abstract A019: Phase 1, first-in-human, dose-expansion study of oral TP-1287, a cyclin dependent kinase 9 (CDK9) inhibitor, in patients with sarcoma 2022 ·Clinical Cancer Research ·Andrew J. Wagner, Gregory M. Coté, Donald Richards, Nicholas J. Vogelzang, William J. Edenfield, Mitchell E. Gross, Lynn Mar, (unknown), Edward Dow, John A. Charlson	1
4	Phase 1/2, Open-Label, Dose Escalation, Dose Expansion Study of Menin Inhibitor DSP-5336 in Adult Patients (pts) with Acute Leukemia with and without Mixed-Lineage Leukemia (MLL)-Rearrangement or Nucleophosmin 1 (NPM1) Mutation 2021 ·Blood ·Naval Daver, (unknown), Hongliang Cai, (unknown), Edward Dow, Ken Eguchi, (unknown), Jay Stoudemire, (unknown), Philip Komarnitsky	2
5	Evolution of replacement therapy for von Willebrand disease: From plasma fraction to recombinant von Willebrand factor 2019 ·Blood Reviews ·Flora Peyvandi, Peter A. Kouides, Peter L. Turecek, Edward Dow, Erik Berntorp	35
6	Phase I open-label, ascending dose trial of AGEN1884, an anti-CTLA-4 monoclonal antibody, in advanced solid malignancies: Dose selection for combination with PD-1 blockade. 2018 ·Journal of Clinical Oncology ·Breelyn A. Wilky, Priya Kumthekar, Robert Wesolowski, Jimmy J. Hwang, Steven I. Park, Igor Proscurshim, Guojun Yuan, Christopher D. Dupont, Olga Shebanova, Jean-Marie Cuillerot, Edward Dow, Jeffrey J. Raizer, (unknown), (unknown), Elise E. Drouin, Nicholas S. Wilson, John M. Goldberg, Jennifer S. Buell, Robert B. Stein	2
7	Comparative Effectiveness Research on the Treatment Outcomes of Subcutaneous (SC) and Intravenous (IV) Bortezomib (BTZ) in Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts) 2015 ·Blood ·Robert M. Rifkin, Esprit Ma, Robyn K. Harrell, Yanyan Zhu, Edward Dow, Liviu Niculescu, Vijayveer Bonthapally	1
8	Comprehensive Genomic Profiling of Advanced Penile Carcinoma Suggests a High Frequency of Clinically Relevant Genomic Alterations 2015 ·The Oncologist ·Siraj M. Ali, Sumanta K. Pal, Kai Wang, Norma Alonzo Palma, Eric M. Sanford, Mark Bailey, Jie He, Julia A. Elvin, Juliann Chmielecki, Rachel M. Squillace, Edward Dow, Deborah Morosini, Jamie Buell, Roman Yelensky, Doron Lipson, Garrett M. Frampton, Peter M. Howley, Jeffrey S. Ross, Philip J. Stephens, Vincent A. Miller	61
9	Effect of cumulative bortezomib dose on survival in multiple myeloma patients receiving bortezomib‐melphalan‐prednisone in the phase III VISTA study 2015 ·American Journal of Hematology ·María‐Victoria Mateos, Paul G. Richardson, Meletios Α. Dimopoulos, Antonio Palumbo, Kenneth C. Anderson, Hongliang Shi, Jennifer Elliott, Edward Dow, Helgi van de Velde, Liviu Niculescu, Jesús F. San Miguel	50
10	Subcutaneous (SQ) Bortezomib (BTZ) in Patients (Pts) with Relapsed Mantle Cell Lymphoma (MCL): Retrospective, Observational Study of Treatment Patterns and Outcomes in US Community Oncology Practices 2014 ·Blood ·Alan P Skarbnik, Esprit Ma, Marie‐Hélène Lafeuille, Jonathan Fortier, Tatyana Feldman, Mei Sheng Duh, (unknown), Helgi van de Velde, Edward Dow, Liviu Niculescu, Vijayveer Bonthapally, André Goy	1
11	Higher Cumulative Bortezomib Dose Results In Better Overall Survival (OS) In Patients With Previously Untreated Multiple Myeloma (MM) Receiving Bortezomib-Melphalan-Prednisone (VMP) In The Phase 3 VISTA Study 2013 ·Blood ·María‐Victoria Mateos, Paul G. Richardson, Hongliang Shi, Liviu Niculescu, Jennifer Elliott, Edward Dow, Helgi van de Velde, Jesús F. San Miguel	7
12	Impact Of Route Of Bortezomib (B) Administration On Dose Intensity and Time To Dose Reduction In Previously Untreated Patients (Pts) With Multiple Myeloma (MM) 2013 ·Blood ·Robert M. Rifkin, Clara Chen, Rahul Dhanda, (unknown), (unknown), Esprit Ma, Yanyan Zhu, Edward Dow, Liviu Niculescu	2
13	A Phase I/II Study of LY900003, an Antisense Inhibitor of Protein Kinase C-α, in Combination with Cisplatin and Gemcitabine in Patients with Advanced Non–Small Cell Lung Cancer 2004 ·Clinical Cancer Research ·Miguel A. Villalona‐Calero, Paul S. Ritch, José A. Figueroa, Gregory A. Otterson, Robert J. Belt, Edward Dow, (unknown), (unknown), (unknown), George Miller, Manuel Modiano, Manuel Valdivieso, Richard S. Geary, Jennifer Oliver, Jon Holmlund	66
14	Combined paclitaxel, cisplatin, and etoposide for patients with previously untreated esophageal and gastroesophageal carcinomas 1999 ·Cancer ·Jacob J. Lokich, Henry Sonneborn, (unknown), Murray M. Bern, (unknown), Edward Dow, (unknown)	31
15	The multifractionated, twice-weekly dose schedule for a three-drug chemotherapy regimen 1999 ·Cancer ·Jacob J. Lokich, (unknown), Murray M. Bern, (unknown), Edward Dow	13

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact